Navigation Links
Wilmot researchers create new way to study liver cancer
Date:3/7/2012

Researchers at the University of Rochester Medical Center's James P. Wilmot Cancer Center have made significant strides in the study of a primary cancer of the liver Intrahepatic Cholangiocarcinoma (IHCC), also called biliary tract cancer. Their work has been published online and in print editions of Cancer Research, the most frequently cited cancer journal in the world.

Aram Hezel, M.D., an assistant professor of Hematology/Oncology in the Department of Medicine at URMC, is the corresponding author of the study that examined the role of genes commonly mutated in human cancers and their role in the growth of Intrahepatic Cholangiocarcinoma, a form of bile duct cancer.

Hezel and fellow researchers from URMC and Massachusetts General Hospital /Harvard Medical School succeeded in developing the first genetically engineered mouse model of IHCC that they hope will provide a valuable, new tool in further research of this disease. A mouse model is important to researchers as it enables them to test dozens or even hundreds of potential treatments in mice in a short span of time, accelerating the discovery process.

The model Hezel and his team created incorporates two of the most common mutations in humans activating mutations of Kras and deletion of p53 oncogenes. An oncogene is a modified gene that increases the malignancy of a tumor cell. Some oncogenes, usually involved in early stages of cancer development, increase the chance that a normal cell develops into a tumor cell, possibly resulting in cancer.

"This is a new model of a less common liver tumor that we have not yet had good ways to study," Hezel said. This represents the first good model that can be used as a tool to try to better understand this disease."

Intrahepatic Cholangiocarcinoma is a primary cancer of the liver. It is thought to arise from the bile ducts, a series of branching tubes within the liver that deliver bile (which is produced by the liver) to the gallbladder and small intestine. Bile breaks down fats found in foods and also helps the body get rid of waste material filtered out of the bloodstream by the liver.

The disease is diagnosed in approximately 6,000 people per year, and its occurrence is rising at a rate that makes it among the fastest growing liver cancers, for reasons scientists have not yet been able to pinpoint. Some suspect that it may be due to doctors having better tests to diagnose this type of cancer more accurately. The tumors are typically very aggressive and highly prone to metastasis at an early stage, leading to poor prognosis. To date, many aspects of IHCC's biology and genetic makeup, as well as its cells of origin, have eluded scientists.

The model provides a relevant foundation for further understanding of the earliest, precancerous stages of IHCC, a better understanding of the tumor biology, and for evaluating effective treatments. The group has found that chloroquine - a drug commonly used to treat malaria has been effective in treating IHCC in the mouse model.

"We've not yet had good ways to study these mutations and their effects on the biliary system in humans," Hezel stated. "Among the problems with understanding this cancer is trying to get a handle on where these tumors come from and what steps lead up to them. We tend not to have lots of biopsies of the liver. Effective screening tests for other cancers provide samples that can be studied and provide an indication of where that cancer is coming from; that's not the case with this form of cancer. We've been able to make genetic changes as seen in humans and place it in a mouse model. By studying mice, we think we can learn what cells the disease comes from. We hope we have provided step upward towards a better view of the disease, both for ourselves and for others studying it."


'/>"/>

Contact: Michael Tedesco
michael_tedesco@urmc.rochester.edu
585-276-5788
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers develop first theranostic treatment for acute lymphoblastic leukemia (ALL)
2. Researchers find possible genetic keys to surviving epithelial ovarian cancer
3. Researchers discover possible approach to the treatment of aggressive breast cancer
4. Researchers ID gene behind primary cervical dystonia, a neck-twisting disorder
5. Researchers find sarcoma tumor immune response with combination therapy
6. Mayo researchers provide atomic view of a histone chaperone
7. Researchers find potential solution to melanomas resistance to vemurafenib
8. Kessler Foundation researchers present at DC Conference on Race, Ethnicity and Disabilities
9. Researchers Spot Genes Behind Macular Degeneration
10. 90 percent of firefighters exhibit symptoms of PTSD according to Ben-Gurion University researchers
11. New blood test for early cancer detection developed by Ben-Gurion University researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... Conn., has relocated its corporate headquarters to a new, more expansive office space ... In October 2016, Qualidigm purchased a distressed office building in Wethersfield, Conn. located ...
(Date:3/28/2017)... ... ... The Executives, Staff & Clients of MGE: Management Experts joined forces with ... Campaign at their Semi-Annual Graduation and Fundraiser Event at MGE’s St. Petersburg Office. , ... 14 internationally in literacy. Statistically, a direct relation can be a found between illiteracy ...
(Date:3/28/2017)... Square, PA (PRWEB) , ... March 28, 2017 , ... ... online and across a variety of business channels. , While many results are ... of any public relations program. , When it comes to measurement, firms should ...
(Date:3/28/2017)... ... March 28, 2017 , ... Thank you to all who attended Capio ... , This event was exclusive to providers and offered an opportunity to collaborate and ... at the Manchester Grand Hyatt where attendees gathered for a lively discussion on trends ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... braces. People who want straight teeth without the extensive time commitment and aesthetic ... FL, without acquiring a referral. A custom-designed series of virtually invisible aligners are ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017 On Friday, benchmark ... Composite closed the trading session up 0.19%; the Dow ... 500 was down 0.08%. US markets made broad based ... day in green. Pre-market today, Stock-Callers.com reviews these four ... (NASDAQ: WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx Group Inc. ...
(Date:3/27/2017)... 2017 Cota Healthcare, the leading ... medicine, today announced the signing of a ... to help improve clinical and cost outcomes ... part of this agreement, which expands significantly ... January 2016, teams from across Novartis Pharmaceuticals ...
(Date:3/24/2017)... 2017 Research and Markets has announced ... report to their offering. ... The Cell Therapy Manufacturing Market, 2017-2027 ... of cell therapy manufacturing and focuses both on contract manufacturers ... are anticipated to emerge as viable alternatives to conventional treatment ...
Breaking Medicine Technology: